How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,000 results for

Hypertension Management for Specific Populations

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy

Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy Guidelines Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy Sonia Butalia, BSc, MD, MSc, a,b,c Francois Audibert, MD, MSc, d Anne-Marie Côt e, MD, MHSc, e Tabassum Firoz, MD, MSc, f Alexander G. Logan, MD, g Laura A. Magee, MD, MSc, h,i William Mundle, MD, j Evelyne Rey, MD, MSc, k Doreen M. Rabi, MD, MSc, a,b,c Stella S. Daskalopoulou, MD, PhD, l and Kara A. Nerenberg, MD (...) and Gynecology, CHU Sainte Justine, Montr eal, Qu ebec, Canada; l Division of General Internal Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada; m Departments of Medicine, Obstetrics and Gynecology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada ABSTRACT We present Hypertension Canada’s inaugural evidence-based Cana- dian recommendations for the management of hypertension in preg- nancy. Hypertension in pregnancy is common, affecting approximately

2018 CPG Infobase

2. Hypertension in pregnancy: diagnosis and management

taken in by babies are very small and would be unlikely to have any clinical effect Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 30 of 54most medicines are not tested in pregnant or breastfeeding women, so disclaimers in the manufacturer's information are not because of any specific safety concerns or evidence of harm. Make decisions on treatment (...) Hypertension in pregnancy: diagnosis and management Hypertension in pregnancy: diagnosis Hypertension in pregnancy: diagnosis and management and management NICE guideline Published: 25 June 2019 www.nice.org.uk/guidance/ng133 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Hypertension Management for Specific Populations

Hypertension Management for Specific Populations Hypertension Management for Specific Populations Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Hypertension Management for Specific Populations Hypertension Management for Specific Populations Aka: Hypertension Management for Specific Populations , Antihypertensives for Specific Populations From Related Chapters II. Approach: Young Hypertensive Pathophysiology Active Increased sympathetic tone Elevated Plasma Activity (PRA) First choice medications or Other medications Beta-alpha antagonist Alpha-1 antagonist Avoid s Decreased HDL Sexual activity and affected III. Approach: Athletes

2018 FP Notebook

4. Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents

Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents IV. Global Vascular Protection Therapy for Adults with Hypertension without Compelling Indications for Specific Agents | Hypertension Canada Guidelines Subgroup Members: Ross D. Feldman, MD; Ernesto L. Schiffrin, MD PhD; Robert A. Hegele, MD; Philip A. McFarlane, MD PhD; Andrew Pipe, CM MD; Paul Oh, MD; Peter Selby, MBBS MHSc; Milan Gupta, MD Central Review Committee: Stella S (...) should be guided by automated office BP measurements (see Diagnosis and Assessment Guidelines , Section I [Accurate measurement of BP], and Supplemental Table S2 [Recommended Technique for Automated Office BP]). Patient selection for intensive management is recommended and caution should be taken in certain high-risk groups (Table 4; Grade B). Background 1. Statin therapy is recommended in hypertensive patients with 3 or more cardiovascular risk factors as defined in (Grade A in patients >40 years

2018 Hypertension Canada

5. Indications for Drug Therapy for Adults With Hypertension Without Compelling Indications for Specific Agents

Indications for Drug Therapy for Adults With Hypertension Without Compelling Indications for Specific Agents II. Indications for Drug Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents | Hypertension Canada Guidelines Subgroup Members: George K. Dresser, MD PhD; Robert J. Herman, MD; Pavel Hamet, MD PhD; Ellen Burgess, MD; Richard Lewanczuk, MD PhD; Jean C. Grégoire, MD; Steven E. Gryn, MD; Luc Poirier, BPharm MSc Central Review Committee: Stella S (...) management emphasize the importance of cardiovascular risk assessment when making treatment decisions. It is well known the risk of cardiovascular disease in hypertensive patients with identical blood pressure (BP) readings can vary more than 10-fold, depending on presence of other cardiovascular risk factors, hypertension-related complications, cardiovascular diseases or other illnesses . Patients with Stage II hypertension (≥160/100 mmHg), those with known cardiovascular disease, and those

2018 Hypertension Canada

6. Choice of therapy for Adults With Hypertension Without Compelling Indications for Specific Agents

Choice of therapy for Adults With Hypertension Without Compelling Indications for Specific Agents III. Choice of therapy for adults with hypertension without compelling indications for specific agents | Hypertension Canada Guidelines Subgroup Members: George K. Dresser, MD PhD; Robert J. Herman, MD; Pavel Hamet, MD PhD; Ellen Burgess, MD; Richard Lewanczuk, MD PhD; Jean C. Grégoire, MD; Steven E. Gryn, MD; Luc Poirier, BPharm MSc Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (...) -acting calcium channel blocker (CCB) (Grade B). ‘Hypertension without compelling indications’ refers to patients with hypertension but without other identified comorbid conditions (such as diabetes mellitus or heart disease) that represent compelling indications for specific drug therapy. Randomized controlled trials have shown that antihypertensive therapy in these patients can reduce incidence of cardiovascular disease by 20% to 30%, depending on the specific outcome considered . Reduction

2018 Hypertension Canada

7. ESC/ESH Management of Arterial Hypertension

, hypertension remains the major preventable cause of cardiovascular disease (CVD) and all-cause death globally and in our continent. These 2018 ESC/ESH Guidelines for the management of arterial hypertension are designed for adults with hypertension, i.e. aged ≥18 years. The purpose of the review and update of these Guidelines was to evaluate and incorporate new evidence into the Guideline recommendations. The specific aims of these Guidelines were to produce pragmatic recommendations to improve (...) ESC/ESH Management of Arterial Hypertension We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2018 ESC/ESH Guidelines for the management of arterial hypertension | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation

Full Text available with Trip Pro

2018 European Society of Cardiology

8. Prevention & Treatment of Hypertension - Health Behaviour Management

and lack of quality social support increased the risk of coronary artery disease similar to more conventional risk factors such as smoking, dyslipidemia and hypertension. These findings suggest a link between psychosocial factors and atherosclerosis; however, the specific nature of the association is not known, and it still remains unclear exactly what the role of stress management on long-term outcomes related to hypertension morbidity may be . However, while there is no evidence that stress (...) Prevention & Treatment of Hypertension - Health Behaviour Management I. Health Behaviour Management | Hypertension Canada Guidelines Subgroup Members: Simon L. Bacon, PhD; Janusz Kaczorowski, PhD; Luc Trudeau, MD; Swapnil Hiremath, MD MPH; Norman RC. Campbell, MD; Michael Roerecke, PhD; Joanne Arcand, PhD RD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C

2018 Hypertension Canada

9. Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations (PubMed)

Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations As part of the Heart Healthy Lenoir Project, we developed a practice level intervention to improve blood pressure control. The goal of this study was: (i) to determine if single nucleotide polymorphisms (SNPs) that associate with blood pressure variation, identified in large studies, are applicable to blood pressure control in subjects from a rural population; (ii) to measure the association (...) in making patient-specific interventions may help providers with making decisions to improve patient outcomes. Further investigation is required to determine the role of this genetic variance with respect to the management of hypertension such that more precise treatment recommendations may be made in the future as part of personalized medicine.

Full Text available with Trip Pro

2018 Journal of personalized medicine

10. Management of specific situations in polycythaemia vera and secondary erythrocytosis

made. Management of specific situations in polycythaemia vera Thrombosis Thrombotic events are the major cause of morbidity and mortality in PV, and their prevention is the main objective of treatment. About one‐third of patients present with a thrombotic event (Elliott & Tefferi, ; Hultcrantz et al , ; Kaifie et al , ) and younger patients diagnosed with PV have an increased risk of early death from cardiovascular disease over the general population, accounting for 45% of all deaths in PV (...) Management of specific situations in polycythaemia vera and secondary erythrocytosis A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis - McMullin - 2019 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline

Full Text available with Trip Pro

2018 British Committee for Standards in Haematology

11. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

be drawn from studies of older populations who do not specifically have CKD. While there is some evidence regarding the treatment of high blood pressure in much older people (that is, older than 80 years of age) from the Hypertension in the Very Elderly Trial (HYVET), 98 it applies to a blood pressure target of 150/80 mmHg in patients with CKD who have an eGFR greater than 40 ml/min/1.73m 2 . The KDIGO guidelines 21 suggests tailoring blood pressure treatment in older patients with CKD to consider age (...) Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac

2017 Association of British Clinical Diabetologists

12. Pharmacological Management of Hypertension

of the benefits and harms of specific blood pressure targets with patients. African American Patients For the general African American population, including those with diabetes, VA/DoD and the JNC 8 Panel agree that monotherapy with an ACEI or ARB is not recommended, and that initial antihypertensive treatment should include a thiazide-type diuretic or CCB. Noting a potential conflict between their recommendation to use an ACEI or ARB in those with CKD and hypertension and the subsequent recommendation to use (...) diuretics as first-line therapy. With regard to selection of a specific agent in this class, the developer suggests chlorthalidone or indapamide over hydrochlorothiazide. In contrast, JNC 8 makes a moderate recommendation for the use of any of the following classes of drugs for the initial treatment of the nonblack population with hypertension: thiazide-type diuretics; CCBs; ACEIs or ARBs. According to the Panel, each of these four drug classes yielded comparable effects on overall mortality

2017 National Guideline Clearinghouse (partial archive)

13. Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pancreas Committee

Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pancreas Committee Copyright © ESPGHAN and NASPGHAN. All rights reserved. Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pancreas Committee Maisam Abu-El-Haija, y Soma Kumar, z Jose Antonio Quiros (...) and to assess for organ involvement. Calcium and triglyceride levels should be considered baseline investigations (9). Monitoring respi- ratory status can alert the clinician to the progression from mild to moderately severe or severe AP. JPGN Volume 66, Number 1, January 2018 Management of Acute Pancreatitis in the Pediatric Population www.jpgn.org 161 Copyright © ESPGHAN and NASPGHAN. All rights reserved. Etiologies As mentioned previously, anatomic, obstructive (including biliary), infectious, trauma

2018 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

14. Diagnosing hypertension in Indigenous Canadians (DREAM-GLOBAL): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. (PubMed)

awareness, treatment, and control, in remote and vulnerable patient populations. The primary objective of this randomized controlled study was to assess the effect of active (with hypertension specific management SMS) or passive (health behaviors SMS alone) on the difference in blood pressure (BP) reduction between the active and passive SMS groups in hypertensive Canadian First Nations people from six rural and remote communities. Pragmatic features of the study included shifting of BP measures to non (...) , mobile health technologies, and patient engagement to support better management of hypertension in Canadian First Nations communities. The active hypertension specific SMS did not lead to improvements in BP control.©2018 Wiley Periodicals, Inc.

Full Text available with Trip Pro

2019 Journal of clinical hypertension (Greenwich, Conn.)

15. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association

of overweight and obesity 6 in the general population and in patients with increased cardiovascular risk, and a recent report from the Eighth Joint Na- tional Committee addressed the management of hypertension. 7 However, these guidelines did not specifically address the management of such comorbidities in patients with HF. Similarly, the most recent ACCF/AHA HF practice guidelines 8 in 2013 addressed the overall management of comorbidities in patients with HF in broad terms, but again, specific (...) professionals and patients on the management of these comorbidities. Recommendations in this document are based on published studies and the multidisciplinary expertise of the writing group and harmonized with published practice guidelines from the ACC/AHA 4–6,8–12 and other organizations. 7,13–15 HypEr TENSIoN AND HF Hypertension is a worldwide epidemic; in many countries, 50% of the population >60 years of age has hypertension. Hypertension is defined as a repeatedly elevated blood pressure (BP) exceeding

Full Text available with Trip Pro

2016 American Heart Association

16. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk, and therapy

The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk, and therapy The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy - Canadian Journal of Cardiology Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 28 (...) , Issue 3, Pages 270–287 The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy x Stella S. Daskalopoulou Affiliations Division of General Internal Medicine, McGill University, Montreal, Québec, Canada Correspondence Corresponding author: Dr Stella S. Daskalopoulou, McGill University, McGill University Health Centre, Montreal General Hospital, 1650 Cedar Avenue, B2.101.4, Montreal

2012 CPG Infobase

17. Prospective external validation of the Predicting Out-of-OFfice Blood Pressure (PROOF-BP) strategy for triaging ambulatory monitoring in the diagnosis and management of hypertension: observational cohort study. (PubMed)

%, 46% to 52%) being referred for ABPM and the remainder managed on the basis of their clinic measurements. Of these, 69 (8%, 6% to 10%) would have received treatment deemed unnecessary had they received ABPM.In a population of patients referred for ABPM, this new triaging approach accurately classified hypertensive status for most, with half the utilisation of ABPM compared with usual care. This triaging strategy can therefore be recommended for diagnosis or management of hypertension in patients (...) Prospective external validation of the Predicting Out-of-OFfice Blood Pressure (PROOF-BP) strategy for triaging ambulatory monitoring in the diagnosis and management of hypertension: observational cohort study. To prospectively validate the Predicting Out-of-OFfice Blood Pressure (PROOF-BP) algorithm to triage patients with suspected high blood pressure for ambulatory blood pressure monitoring (ABPM) in routine clinical practice.Prospective observational cohort study.10 primary care practices

Full Text available with Trip Pro

2018 BMJ

18. Hypertension - Diagnosis and Management

for CVD MOBP = 160/100 AOBP , ABPM, HBPM = 155/95 1+ co-morbidities OR high-risk for CVD MOBP = 180/110 AOBP , ABPM, HBPM = 175/105 Consider 24-hour ambulatory or home BP monitoring, if appropriate. ABPM (mean 24-hour) 130/80 = 140/90 MOBP ABPM (mean awake) 135/85 = 140/90 MOBP HBPM 135/85 = 140/90 MOBP Appendix A: Diagnosis and Management of Hypertension Algorithm Lifestyle management Conduct a patient-specific discussion to decide upon desirable BP readings. Pharmacologic management (first-line (...) : Refer to BCGuidelines.ca – Thyroid Function Tests in the Diagnosis and Monitoring of Adults. Initial Investigations: • Thyroid-stimulating hormone (TSH) Hyperparathyroidism Signs/symptoms: • Bone pain • Non-specific symptoms • Patients often asymptomatic Initial Investigations: • Parathyroid hormone (PTH) • Ionized calcium • PhosphateBCGuidelines.ca: Hypertension – Diagnosis and Management: Appendix D (2015, Revised 2016) 1 Appendix D: Commonly Used Antihypertensive Drugs 1-4, a Generic Name (trade

2015 Clinical Practice Guidelines and Protocols in British Columbia

19. Hypertension - Diagnosis and Management

is ≥ 160/100; or Desirable BP is not reached with lifestyle management. Treatment of Hypertension without Specific Indications In general, antihypertensive medications are equally effective in lowering BP. When prescribing one, take into account cost of the drug, any side-effects and any potential contraindications. For a list of commonly prescribed antihypertensive medications in each class, refer to Without specific indications, consider monotherapy with one of the following first-line drugs (...) Hypertension - Diagnosis and Management Hypertension - Diagnosis and Management - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend theme_5_collection theme_5_frontend Driving

2015 Clinical Practice Guidelines and Protocols in British Columbia

20. Hypertension in adults: diagnosis and management

Hypertension in adults: diagnosis and management Hypertension in adults: diagnosis and Hypertension in adults: diagnosis and management management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in adults: diagnosis and management (CG127) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents Introduction 4 Person

2011 National Institute for Health and Clinical Excellence - Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>